APP and early-onset autosomal dominant Alzheimer disease: Consistent with our results, it has been reported that an AsA treatment improves spatial memory in APP/PSEN1 mice, a mouse model for Alzheimer’s disease, but does not alter monoamine levels in the nucleus accumbens.(42) In the meantime, AsA appears to play a protective role against the excessive action of glutamate receptor in dopaminergic neurons,(4) which suggests that the modulation of cellular signaling may be involved in spatial memory formation.